Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic Biosciences (NASDAQ:XBIO) announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development, participated in a Virtual Investor 'What This Means' segment. The segment focuses on discussing the company's recently announced extension of its Research Agreement with the University of Virginia for advancing its DNase-Based oncology platform, which aims to address hard-to-treat cancers.
Xenetic Biosciences (NASDAQ:XBIO) ha annunciato che il Dr. Reid Bissonnette, Consulente Esecutivo per la Ricerca e lo Sviluppo Traslazionale, ha partecipato a un segmento virtuale per investitori intitolato 'Cosa significa questo'. Il segmento si concentra sulla discussione dell'estensione recentemente annunciata del suo Accordo di Ricerca con l'Università della Virginia per promuovere la sua piattaforma oncologica basata su DNasi, che mira a trattare i tumori difficili da curare.
Xenetic Biosciences (NASDAQ:XBIO) anunció que el Dr. Reid Bissonnette, Consultor Ejecutivo de Investigación y Desarrollo Traslacional, participó en un segmento virtual para inversores titulado 'Qué significa esto'. El segmento se centra en discutir la extensión recientemente anunciada de su Acuerdo de Investigación con la Universidad de Virginia para avanzar en su plataforma oncológica basada en DNasa, que tiene como objetivo abordar los cánceres difíciles de tratar.
Xenetic Biosciences (NASDAQ:XBIO)는 전임상 연구 및 개발을 위한 수석 컨설턴트인 리드 비소네트 박사가 '이것은 무엇을 의미하는가'라는 제목의 가상 투자자 세션에 참여했다고 발표했습니다. 이 세션은 버지니아 대학교와의 연구 계약 연장에 대한 논의에 중점을 두고 있으며, 이는 DNase 기반의 온콜로지 플랫폼을 발전시키기 위한 것으로, 치료하기 어려운 암을 대상으로 하고 있습니다.
Xenetic Biosciences (NASDAQ:XBIO) a annoncé que Dr. Reid Bissonnette, Consultant Exécutif pour la Recherche et le Développement Translationnel, a participé à un segment d'investisseur virtuel intitulé 'Ce que cela signifie'. Le segment se concentre sur la discussion de l'extension récemment annoncée de son Accord de Recherche avec l'Université de Virginie pour faire avancer sa plateforme oncologique basée sur la DNase, qui vise à traiter les cancers difficiles à traiter.
Xenetic Biosciences (NASDAQ:XBIO) gab bekannt, dass Dr. Reid Bissonnette, Strategischer Berater für Translationale Forschung und Entwicklung, an einem virtuellen Investorensegment mit dem Titel 'Was bedeutet das?' teilnahm. Das Segment konzentriert sich auf die Diskussion über die kürzlich angekündigte Verlängerung des Forschungsabkommens mit der Universität von Virginia, um ihre DNase-basierte Onkologieplattform voranzutreiben, die darauf abzielt, schwer behandelbare Krebserkrankungen anzugehen.
- Extended research agreement with University of Virginia for DNase-Based oncology platform
- None.
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform
FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment
As part of the segment, Dr. Bissonnette discussed the Company's recently announced extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform.
The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: ongoing pre-clinical studies with data expected before year end; focusing on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications, the potential of our DNase-based oncology platform, focusing our resources on driving our pipeline towards first-in-human clinical studies and establishing proof-of-concept in multiple indications, our commitment to bringing a much-needed, innovative immune-oncology treatment to patients and generate shareholder value in the near and long term, and plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What is the purpose of Xenetic Biosciences' research agreement with University of Virginia?
What is XBIO's latest development in oncology research?
What did Dr. Reid Bissonnette discuss in the Virtual Investor segment for XBIO?
What is Xenetic Biosciences' (XBIO) current research focus?
